These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18670307)

  • 41. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
    J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
    Uhm JE; Park BB; Ahn MJ; Lee J; Ahn JS; Kim SW; Kim HT; Lee JS; Kang JH; Cho JY; Song HS; Park SH; Sohn CH; Shin SW; Choi JH; Park K
    J Thorac Oncol; 2009 Sep; 4(9):1136-43. PubMed ID: 19687764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
    Mok T; Wu YL; Au JS; Zhou C; Zhang L; Perng RP; Park K
    J Thorac Oncol; 2010 Oct; 5(10):1609-15. PubMed ID: 20808255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Galetta D; Colantuoni G; Del Gaizo F; Ferrara C; Guerriero C; Nicolella D; Rossi A
    J Thorac Oncol; 2007 Aug; 2(8):758-61. PubMed ID: 17762344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
    Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
    J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
    Suleiman AA; Frechen S; Scheffler M; Zander T; Kahraman D; Kobe C; Wolf J; Nogova L; Fuhr U
    J Thorac Oncol; 2015 Jan; 10(1):84-92. PubMed ID: 25226426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
    Drobnienė M; Cicėnienė A; Zelvienė TP; Grigienė R; Lachej N; Steponavičienė L; Aleknavičius E
    Medicina (Kaunas); 2011; 47(9):520-5. PubMed ID: 22156604
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
    Marquez-Medina D; Chachoua A; Martin-Marco A; Desai AM; Garcia-Reglero V; Salud-Salvia A; Muggia F
    Clin Transl Oncol; 2013 Nov; 15(11):959-64. PubMed ID: 23606352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
    Nakagawa K; Kudoh S; Ohe Y; Johkoh T; Ando M; Yamazaki N; Seki A; Takemoto S; Fukuoka M
    J Thorac Oncol; 2012 Aug; 7(8):1296-303. PubMed ID: 22610257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
    Wang Q; Wang H; Li P; Zhu H; He C; Wei B; Ma J; Ma Z
    Am J Med Sci; 2010 Oct; 340(4):321-5. PubMed ID: 20601859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
    Hesketh PJ; Chansky K; Wozniak AJ; Hirsch FR; Spreafico A; Moon J; Mack PC; Marchello BT; Franklin WA; Crowley JJ; Gandara DR
    J Thorac Oncol; 2008 Sep; 3(9):1026-31. PubMed ID: 18758306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.
    Perng RP; Yang CH; Chen YM; Chang GC; Lin MC; Hsieh RK; Chu NM; Lai RS; Su WC; Tsao CJ; Hsia TC; Chen HC; Chen CH; Huang MS; Wang JL; Ho ML; Chung CY; Yu CJ; Chang WC; Kuo HP; Yu CT; Lin ZZ; Kao WY
    Lung Cancer; 2008 Oct; 62(1):78-84. PubMed ID: 18423781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
    Lewis G; Peake M; Aultman R; Gyldmark M; Morlotti L; Creeden J; de la Orden M
    J Int Med Res; 2010; 38(1):9-21. PubMed ID: 20233509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Erlotinib in non-small cell lung cancer: experience of clinical hospital for lung diseases Jordanovac].
    Plestina S; Samarzija M; Plestina S; Chalfe N; Zuljević E
    Lijec Vjesn; 2007 Dec; 129(12):387-90. PubMed ID: 18383740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
    Carbone DP; Ding K; Roder H; Grigorieva J; Roder J; Tsao MS; Seymour L; Shepherd FA
    J Thorac Oncol; 2012 Nov; 7(11):1653-60. PubMed ID: 23059783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].
    Debieuvre D; Moreau L; Coudert M; Locher C; Asselain B; Coëtmeur D; Dayen C; Goupil F; Martin F; Brun P; De Faverges G; Hauss PA; Gally S; Ben Hadj Yahia B; Grivaux M
    Rev Mal Respir; 2019 Jun; 36(6):649-663. PubMed ID: 31204231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.
    Lind JS; Postmus PE; Smit EF
    J Thorac Oncol; 2010 Apr; 5(4):554-7. PubMed ID: 20357621
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib].
    Liu Y; Guo J; Wang Y; Yang J; Wang Z
    Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):785-9. PubMed ID: 22008108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
    Shao L; Hong W; Zheng L; He C; Zhang B; Xie F; Song Z; Lou G; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2014 May; 17(5):391-400. PubMed ID: 24854556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.